1996
DOI: 10.1007/bf02628659
|View full text |Cite
|
Sign up to set email alerts
|

Orally administered HSV-specific transfer factor (TF) prevents genital or labial herpes relapses

Abstract: Forty-four patients suffering from genital (22) and labial (22) herpes were orally treated with HSV-1/2-specific transfer factor (TF). TF was obtained by in vitro replication of a HSV-1/2-specific bovine dialysable lymphocyte extract. Treatment was administered bi-weekly the first 2 weeks, and then weekly for 6 months, most patients received 2-3 courses. The total observation period for all patients before treatment was 26,660 days, with 544 relapses, and a relapse index of 61.2, whereas the cumulative observa… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
8
0
4

Year Published

1996
1996
2019
2019

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 21 publications
(13 citation statements)
references
References 36 publications
1
8
0
4
Order By: Relevance
“…showing antiviral, antibacterial, antitumor, or immunoregulatory activity. PRPs have been experimentally shown to provide immunity to herpes viruses [1,2], vesicular stomatitis virus [3], EpsteinBar virus [4], measles [5], and HIV (human immunodeficiency virus) [6]. Of the many peptide families that can be isolated from all classes of animals, the short proline-rich antibacterial peptides are of particular interest.…”
Section: The Proline-rich Peptide Familymentioning
confidence: 99%
“…showing antiviral, antibacterial, antitumor, or immunoregulatory activity. PRPs have been experimentally shown to provide immunity to herpes viruses [1,2], vesicular stomatitis virus [3], EpsteinBar virus [4], measles [5], and HIV (human immunodeficiency virus) [6]. Of the many peptide families that can be isolated from all classes of animals, the short proline-rich antibacterial peptides are of particular interest.…”
Section: The Proline-rich Peptide Familymentioning
confidence: 99%
“…One of the unique features of STF is that it does not have immunogenicity and genus specificity but the STF prepared by one genus of animals like goat, rabbit, dog, and so forth has the ability of transferring the immunological activity to other genera of animals without causing hypersensitivity. Currently, several STFs have been successfully developed; mainly for herpes simplex virus type 1 (HSV-1) [7], Epstein-Barr virus [8], and Staphylococcus aureus antigens [9]. Also, STFs have been used in therapy of many diseases, for example, lyme, candidiasis, and herpes simplex [10–14].…”
Section: Introductionmentioning
confidence: 99%
“…Han demostrado ser efectivos en corregir la inmunidad celular defi ciente en pacientes con infecciones oportunistas tales como coccidioidomicosis y herpes simple, y en proveer inmunidad contra varicela Zoster en pacientes con leucemia aguda. 8,11,25,26,27,28 Kirkpatrick et al desarrollaron un proceso de purifi cación de factores de transferencia específi cos con homogeneidad aparente, lo que per-Cuadro 4. Estado inmunológico y nutricional antes y después del inicio de tratamiento con extractos dializados de leucocitos en 150 pacientes pediátricos con inmunodefi ciencia celular mitió separar los factores de transferencia individuales de las mezclas que contienen varios de ellos y así demostrar su especifi cidad antigénica.…”
Section: Discussionunclassified